Lux Capital: The “Wait, What?!” Moment of Moving from Tech to Medtech

article image

As medtech innovation expands to include more IT and software elements, so too will the industry’s investor base, increasingly attracting tech VCs who view the world quite differently, as Avail Medsystems found out first-hand.

For all of the science and analytics associated with the go or no-go decision to invest in a start-up company, most venture capitalists will acknowledge that equally important is a certain kind of gut level reaction or “Aha!” moment that flips the switch one way or another. For Peter Hebert, one of the founders of Lux Capital, it was just that kind of experience that convinced him to lead Avail Medsystem Inc.’s Series A and A1 rounds and also to invest in the company’s Series B financing.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: